AngioDynamics (ANGO) Scheduled to Post Earnings on Thursday

AngioDynamics (NASDAQ:ANGO - Get Free Report) is scheduled to announce its earnings results before the market opens on Thursday, April 4th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings results on Friday, January 5th. The medical instruments supplier reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.04. AngioDynamics had a negative return on equity of 1.78% and a negative net margin of 4.28%. The company had revenue of $79.07 million for the quarter, compared to the consensus estimate of $81.65 million. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AngioDynamics Price Performance

Shares of ANGO traded up $0.17 during trading hours on Thursday, reaching $5.87. The stock had a trading volume of 428,809 shares, compared to its average volume of 508,687. AngioDynamics has a 52 week low of $5.26 and a 52 week high of $12.62. The firm has a 50-day moving average of $5.81 and a 200 day moving average of $6.55.

Hedge Funds Weigh In On AngioDynamics

Several hedge funds have recently modified their holdings of ANGO. Point72 Hong Kong Ltd acquired a new stake in AngioDynamics in the 1st quarter valued at about $36,000. US Bancorp DE lifted its position in AngioDynamics by 63.3% during the second quarter. US Bancorp DE now owns 3,691 shares of the medical instruments supplier's stock worth $38,000 after acquiring an additional 1,431 shares during the last quarter. Quarry LP lifted its position in AngioDynamics by 227.4% during the first quarter. Quarry LP now owns 3,899 shares of the medical instruments supplier's stock worth $40,000 after acquiring an additional 2,708 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of AngioDynamics during the third quarter worth approximately $41,000. Finally, Captrust Financial Advisors increased its holdings in shares of AngioDynamics by 95.1% during the first quarter. Captrust Financial Advisors now owns 2,883 shares of the medical instruments supplier's stock worth $62,000 after purchasing an additional 1,405 shares during the period. Institutional investors own 89.43% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ANGO. Raymond James lowered their price objective on shares of AngioDynamics from $12.00 to $10.00 and set an "outperform" rating for the company in a research report on Tuesday, January 9th. HC Wainwright lowered their target price on AngioDynamics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Monday, January 8th.

AngioDynamics Company Profile

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.